News

On July 4, 2025, President Trump signed into law a bill that cuts $1 trillion from the Medicaid program and makes sweeping changes to eligibility, enrollment processes and more. The new requirements don’t go into effect immediately – but we know they are coming. Here are some steps you can take to protect your Medicaid coverage now and, in the future, as the new requirements go into effect.

Do you want to help shape the future of treatments for sickle cell disease (SCD)?

The Sickle Cell Voices Alliance, a partnership of the Sickle Cell Disease Association of America, Inc., the Sickle Cell Disease Association of Canada and Sickle Cell Society, United Kingdom, is hosting an externally led patient-focused drug development (EL-PFDD) meeting.

Masterclass is back! Join us on Tuesday, September 29, for this free, virtual event. Our panel of experts and warriors will explore how new approaches in sickle cell disease care can help improve outcomes and shape how health care is addressed now and in the future.

Recently, new recommendations to the vaccination schedule were issued by executive order. Changes to the vaccination schedule and vaccination recommendations can be confusing to the sickle cell warrior community.

The Sickle Cell Disease Association of America, Inc. (SCDAA) was deeply saddened to hear of the recent loss of Genesis Jones.

In recognition of the Congressional Black Caucus' 55th Annual Legislative Conference, SCDAA is pleased to announce it will host a fall Sickletini on the Hill event!

The Medical Research and Advisory Committee (MARAC) of the Sickle Cell Disease Association of America, Inc., (SCDAA) is saddened to hear the news that Oxbryta® (voxelotor) will not be made available for the treatment of sickle cell disease.

As we get closer to the SCDAA Annual Convention we would like to recognize the amazing work performed by community health workers (CHWs) with the SCDAA CHW P.O.W.E.R. Award. This award recognizes exemplary performance by individuals identified by their supervisors and peers as having consistently excelled in their positions and demonstrated integrity and a strong commitment to the sickle cell disease (SCD) community and values of the community health worker profession.

The Medical Research and Advisory Committee (MARAC) of the Sickle Cell Disease Association of America, Inc., (SCDAA) is excited about the Food and Drug Administration’s (FDA) approval of Casgevy (exagamglogene autotemcel) for sickle cell patients aged 2 years and older. We are encouraged to learn they are “committed to prioritizing and speeding up the review of products that address critical U.S. health priorities,” including sickle cell disease (SCD).